Mimicking rubella virus particles by using recombinant envelope glycoproteins and liposomes

Assembly and characterization of lipid-lipid binding protein particles

Lipid-protein complexes, lipoplexes, are currently of great interest because of their immunogenic, gene free, and low cost properties. For their applications as potential vaccines, it is critical to display a target protein on the surface of lipoplex particles to allow external interactions to take place. However, how to effectively assemble lipoplexes with target proteins externally accessible is a constant challenge. In this study, human liver fatty acid binding protein 1 (hl-FABP1) was used as a model protein in lipoplex assembly with a non-lipid binding protein, bovine serum albumin (BSA), serving as a comparison. The protein-lipid particles were assembled by four different processes and characterized by dynamic light scattering (DLS), transmission electron microscope (TEM), flow cytometry (FCM), and a modified ELISA. Results indicate that by incubating the target protein with pre-formed liposomes at a temperature higher than all transition temperatures (T(m)) of the lipids used through an extended period of time, 1.48×10(-6)nmol per lipoplex of incorporated proteins can be detected by ELISA and are externally accessible. Additional experiments showed that most of those externally accessible proteins are likely embedded in the lipid bilayer structure and are not subject to dissociation from the lipoplex particles at elevated salt concentrations.

Clinical applications of virosomes in cancer immunotherapy

Cancer immunotherapy is increasingly accepted as a treatment option for advanced stage disease. The identification of tumour-associated antigens in 1991 has prompted the development of antigen-specific immunotherapeutic strategies for a variety of cancers. Many of them result in some immunological responses in cancer patients; however, clinical results were not observed concomitantly with immunological responses; therefore, further improvements in the field of immunotherapy are urgently needed. Virosomes are lipidic envelopes devoid of genetic information, but which retain the antigenic profile and fusogenic properties from their viral origin. Virosomes are versatile antigen carriers and can be engineered to perform various tasks in cancer immunotherapy. Preclinical data have fostered the development of innovative clinical protocols. Hence, immunopotentiating reconstituted influenza virosomes will be assessed in breast and melanoma immunotherapy, and may contribute to the development of clinically effective cancer vaccines and ultimately improve patient outcomes. The objective of this review is to provide an overview of the potential clinical applications of virosomes as innovative and potentially effective reagents in active specific cancer immunotherapy.

Preparation of immunoblot test stripes from a Rubella virus-like particles dye crystal complex as antigen

Stably transfected Chinese hamster ovary (CHO24S) cells were the source for Rubella virus-like particles (RVLP) containing all structural proteins (E1, E2, C and their dimers). RVLP are secreted from the CHO24S cells into the medium and the time-point for collecting the medium with the highest yield of >100 kDa proteins (with 17 mg protein from 10 ml cell culture supernatant) was after 2 days of incubation. Different methods for RVLP isolation from the cell culture supernatants were assessed by SDS-PAGE and Western blotting (using sera positive or negative for Rubella virus (RV)-specific antibodies or an anti-E1 monoclonal antibody). A combination of membrane filtration with a rapid, novel gradient ultracentrifugation step (using Coomassie brilliant blue G crystals as adsorbens for RVLP that facilitated virus isolation) was the most suitable technique. 132 RV-positive human sera (RV IgG > 20 IU/ml by commercial ELISA) were tested by our "self made" immunoblot test stripes (using RVLP adsorbed to dye crystals as antigen) for the presence or absence of antibodies specific for RV structural proteins. 57.6% of these sera had antibodies against E1, E2 and C, 31% against E1 and C, and 1.5% against E1 only, whereas 3.8% had no RV specific antibodies and only 6.0% were equivocal which demonstrated that these "self made" test stripes can reliably differentiate RV antibody specificities.

Expression and trafficking of fluorescent viral membrane proteins in baculovirus-transduced BHK cells

Baculovirus vectors show promise as a novel tool for gene delivery into mammalian cells and gene transfer with wild-type baculovirus has been demonstrated both in vitro and in vivo. To study expression and intracellular trafficking of foreign viral membrane proteins in baculovirus-transduced mammalian cells, the envelope proteins, E1 and E2, of rubella virus (RV) were chosen as a model. The enhanced green fluorescent protein (EGFP) and a red fluorescent protein (RFP) were fused to the C-terminus of E1 and E2, respectively. The proteins were cloned under a cytomegalovirus (CMV) promoter and expressed as fluorescent fusion proteins in baculovirus-transduced baby hamster kidney (BHK) cells. Expression of the chimeric proteins in these cells showed that E1 was retained within the ER and cis-Golgi when expressed alone. In contrast, E2 was efficiently transported to the trans-Golgi network (TGN). However, when expressed together, E1 co-localized with E2 in TGN and to some extent in the lysosomes. The recombinant baculovirus vectors were able to transduce the BHK cells efficiently and the fluorescent fusion constructs allowed easy detection of the trafficking events in the transduced mammalian cells. Consequently, this technique should have wide applications when intracellular analysis of protein synthesis and maturation is under study.